SCHEMBL22714871

SCHEMBL22714871

COc1cc(-c2ccc(F)cc2)cc2c(NCC3CC3)ncnc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.44
MAP4K4 O95819 1/20 0.43
RAF1 P04049 1/20 0.43
BRAF P15056 1/20 0.43
MEN1 O00255 1/20 0.42
KHK P50053 1/20 0.42
GAK O14976 1/20 0.41
LMNA P02545 6/20 0.41
CYP1A2 P05177 6/20 0.41
CYP3A4 P08684 6/20 0.41
CYP2D6 P10635 6/20 0.41
CYP2C19 P33261 6/20 0.41
CLK4 Q9HAZ1 6/20 0.41
HSD17B10 Q99714 5/20 0.41
TSHR P16473 5/20 0.41
ALDH1A1 P00352 4/20 0.41
MAPK1 P28482 4/20 0.41
USP2 O75604 4/20 0.41
CYP2C9 P11712 2/20 0.41
HIF1A Q16665 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30297742 1.00 EGFR (0.44) EGFRMAP4K4RAF1BRAFMEN1
SCHEMBL28726549 0.95 EGFR (0.41) EGFRMAP4K4RAF1BRAFMEN1
SCHEMBL28726551 0.95 EGFR (0.41) EGFRMAP4K4RAF1BRAFMEN1
SCHEMBL22744954 0.95 EGFR (0.41) EGFRMAP4K4RAF1BRAFMEN1
SCHEMBL29544029 0.94 EGFR (0.40) EGFRMAP4K4RAF1BRAFMEN1
SCHEMBL22715085 0.93 CSF1R (0.47) EGFRMEN1CYP1A2CYP3A4CYP2D6
SCHEMBL24478390 0.92 LMNA (0.50) EGFRMAP4K4MEN1GAKLMNA
SCHEMBL29481165 0.92 LMNA (0.50) EGFRMAP4K4MEN1GAKLMNA
SCHEMBL28726563 0.91 EGFR (0.39) EGFRMAP4K4RAF1BRAFMEN1
SCHEMBL28726622 0.90 RPS6KB1 (0.41) EGFRMAP4K4RAF1BRAFGAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637451-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-05-26 US claimed
CN-118239931-A As P2X3Aminoquinazoline derivatives of inhibitors 奇斯药制品公司 2024-06-25 CN claimed
CN-114269432-B As P2X3Aminoquinazoline derivatives of inhibitors 奇斯药制品公司 2024-05-07 CN claimed
US-20230092892-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2023-03-23 US claimed
EP-3976179-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2022-04-06 EP claimed
CN-114269432-A As P2X3Aminoquinazoline derivatives as inhibitors 奇斯药制品公司 2022-04-01 CN claimed
WO-2020239951-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2020-12-03 WO claimed
US-20230092892-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2023-03-23 US disclosed
WO-2020239951-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2020-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230092892-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 EGFR 2409/4885MAP4K4 2493/4885RAF1 2603/4885
US-12637451-B2 Amino quinazoline derivatives as P2X3 inhibitors P2RX3, P2RX1, P2RX7 EGFR 1502/4885MAP4K4 3823/4885RAF1 1455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.